Gastroenterology
Volume 137, Issue 5 , Pages 1680-1686, November 2009

Trends in Waiting List Registration for Liver Transplantation for Viral Hepatitis in the United States

  • W. Ray Kim

      Affiliations

    • Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
    • Corresponding Author InformationReprint requests Address requests for reprints to: W. Ray Kim, MD, Division of Gastroenterology and Hepatology (PL 6), 200 1st Street SW, Rochester, Minnesota 55905. fax: (507) 538-3974
  • ,
  • Norah A. Terrault

      Affiliations

    • University of California-San Francisco, San Francisco, California
  • ,
  • Rachel A. Pedersen

      Affiliations

    • Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, Minnesota
  • ,
  • Terry M. Therneau

      Affiliations

    • Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, Minnesota
  • ,
  • Erick Edwards

      Affiliations

    • United Network for Organ Sharing, Richmond, Virginia
  • ,
  • Andrew A. Hindman

      Affiliations

    • Gilead Sciences, Inc, Foster City, California
  • ,
  • Carol L. Brosgart

      Affiliations

    • Gilead Sciences, Inc, Foster City, California

published online 27 July 2009.

Background & Aims

In the last decade, significant progress has been made in the treatment of liver disease associated with chronic hepatitis, especially in patients infected with the hepatitis B virus (HBV). To investigate whether the population-wide application of antiviral therapies has impacted liver transplant waiting list registration, we analyzed longitudinal trends in waiting list registration for patients with hepatitis B and C and those with nonviral liver disease.

Methods

This study represented a retrospective analysis of registry data containing all US liver transplant centers. All adult, primary liver transplantation candidates registered to the Organ Procurement and Transplantation Network between 1985 and 2006 were included in the analysis. Standardized incidence rates were calculated for waiting list registration for liver transplantation by underlying disease (HBV and HCV infection and other) and by indication for transplantation (fulminant liver disease, hepatocellular carcinoma [HCC], and end-stage liver disease [ESLD]).

Results

Of 113,927 unique waiting list registrants, 4793 (4.2%) had HBV, and 40,923 (35.9%) had HCV infections; the remaining 68,211 (59.9%) had neither. The incidence of waiting list registration for ESLD and fulminant liver disease decreased, whereas that for HCC increased. The decrease in ESLD registration was most pronounced, and the increase in HCC was least dramatic among registrants with hepatitis B. The decrease in registration for ESLD secondary to HCV infection was also significantly larger than that for ESLD patients with nonviral etiologies.

Conclusions

The pattern of liver transplantation waiting list registration among patients with hepatitis B suggests that the widespread application of oral antiviral therapy for HBV contributed to the decreased incidence of decompensated liver disease.

Abbreviations used in this paper: FLD, fulminant liver disease, HBV, hepatitis B virus, HCC, hepatocellular carcinoma, HCV, hepatitis C virus, LTx, liver transplantation, OPTN, Organ Procurement and Transplantation Network

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Conflicts of interest The authors disclose the following: W. Ray Kim received a grant from the Gilead Sciences, Inc, to conduct this study. He has served as a consultant for Roche, Bristol–Myers–Squibb, Idenix, Schering-Plough, and Gilead Sciences. Norah Terrault has received grants from Gilead Sciences, Cangene, NABI, and Roche and consulted Bristol-Myers-Squibb. Andrew Hindman was a former employee of Gilead Sciences, Inc, and Carol Brosgart was a former employee of Gilead Sciences. Terry Therneau, Rachel Pedersen, and Erick Edwards disclose no conflicts.

 Funding Supported by grants from the National Institute of Diabetes, Digestive and Kidney Diseases (DK-34238 and DK-61617), and Gilead Sciences, Inc, provided unrestricted grant in partial support of the work; however, the content of the work including data analysis and interpretation was solely that of the authors.

PII: S0016-5085(09)01246-3

doi:10.1053/j.gastro.2009.07.047

Gastroenterology
Volume 137, Issue 5 , Pages 1680-1686, November 2009